Discovering Potential Drug Targets with AI and ML (G25853)

Target Name: DCAF12

NCBI ID: G25853

DCAF12

Discovering Potential Drug Targets with AI and ML

Drug discovery and development are critical processes in the pharmaceutical industry. New treatments and drugs are continually being developed to treat various diseases, and researchers are constantly searching for new and innovative ways to treat them. One promising area of research is the use of artificial intelligence (AI) and machine learning (ML) to identify potential drug targets. One such target is DCAF12 (CT102), a protein that is expressed in various tissues and organs and has been shown to play a role in several diseases, including cancer. In this article, we will discuss the potential of DCAF12 as a drug target and the research that has been done to study its potential.

Potential Drug Target

DCAF12 is a protein that is expressed in various tissues and organs, including the brain, heart, liver, and kidneys. It is a member of the superfamily of transmembrane protein (SMP) and is characterized by a predicted transmembrane extension and a unique topology. DCAF12 has been shown to play a role in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key features of DCAF12 is its ability to interact with various signaling pathways. DCAF12 has been shown to interact with several signaling pathways, including the PI3K/Akt signaling pathway, the TGF-β signaling pathway, and the NF-kappa-B signaling pathway. These interactions make DCAF12 a potential drug target for a variety of diseases.

DCAF12 has also been shown to play a role in several diseases, including cancer. Studies have shown that high levels of DCAF12 are associated with poor prognosis in patients with various cancers, including breast, ovarian, and colorectal cancers. Additionally, DCAF12 has been shown to promote the growth and survival of cancer cells, making it a potential target for cancer treatments.

DCAF12 has also been shown to play a role in neurodegenerative diseases. Studies have shown that DCAF12 is expressed in the brains of individuals with Alzheimer's disease and other forms of neurodegenerative disease. Additionally, DCAF12 has been shown to interact with several neurotransmitters, including dopamine, which is a neurotransmitter that is associated with the progression of neurodegenerative diseases.

DCAF12 has also been shown to play a role in autoimmune disorders. Studies have shown that DCAF12 is expressed in the tissues of individuals with rheumatoid arthritis and other forms of autoimmune disease. Additionally, DCAF12 has been shown to interact with several immune system proteins, including T cells and B cells, which are involved in the development and progression of autoimmune diseases.

Research Efforts

DCAF12 has been a topic of interest for researchers for several years, and various studies have been conducted to study its potential as a drug target. One of the most significant studies was a mouse study conducted by researchers at the University of California, San Diego, which showed that DCAF12 was involved in the development of neurofibrillary tangles, a hallmark of Alzheimer's disease, in mouse models of the disease.

Another study was conducted by researchers at the University of Cambridge, which showed that DCAF12 was involved in the development of cancer in cell cultures. This study raised the potential for DCAF12 to be used as a drug target for cancer.

There have also been several efforts to develop DCAF12-based therapies for various diseases. For example, researchers at the University of California, San Diego have developed a drug that targets DCAF12 and has shown promise in treating

Protein Name: DDB1 And CUL4 Associated Factor 12

Functions: Substrate-recognition component of a DCX (DDB1-CUL4-X-box) E3 ubiquitin-protein ligase complex of the DesCEND (destruction via C-end degrons) pathway, which recognizes a C-degron located at the extreme C terminus of target proteins, leading to their ubiquitination and degradation (PubMed:16949367, PubMed:16964240, PubMed:29779948). The C-degron recognized by the DesCEND pathway is usually a motif of less than ten residues and can be present in full-length proteins, truncated proteins or proteolytically cleaved forms (PubMed:29779948). The DCX(DCAF12) complex specifically recognizes proteins with a diglutamate (Glu-Glu) at the C-terminus, such as MAGEA3, MAGEA6 and CCT5, leading to their ubiquitination and degradation (PubMed:29779948, PubMed:31267705). Ubiquitination of MAGEA3, MAGEA6 by DCX(DCAF12) complex is required for starvation-induced autophagy (PubMed:31267705). Also directly recognizes the C-terminal glutamate-leucine (Glu-Leu) degron as an alternative degron in proteins such as MOV10, leading to their ubiquitination and degradation. Controls the protein level of MOV10 during spermatogenesis and in T cells, especially after their activation (PubMed:34065512)

The "DCAF12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DCAF12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets